(polyphosphorylated PI or diacylglycerol), or partial insertion of hydrophobic domains of the protein into the membrane bilayer (insertion of an amphipathic α-helix). In many cases, the hydrophobic face of an amphipathic helix inserts parallel to the bilayer with the cationic face residing in t...
Study design and participant samples Patients had mUC and were treated with atezolizumab 1200 mg intravenously (IV) every 21 days at Memorial Sloan Kettering Cancer Center as part of the IMVigor210 trial5. Cross sectional imaging was performed every 9 weeks for the first 12 months following c...